Recursion Pharmaceuticals (RXRX) Notes Payables (2020 - 2024)
Historic Notes Payables for Recursion Pharmaceuticals (RXRX) over the last 5 years, with Q1 2024 value amounting to $55000.0.
- Recursion Pharmaceuticals' Notes Payables fell 9167.93% to $55000.0 in Q1 2024 from the same period last year, while for Mar 2024 it was $55000.0, marking a year-over-year decrease of 9167.93%. This contributed to the annual value of $41000.0 for FY2023, which is 5773.2% down from last year.
- Per Recursion Pharmaceuticals' latest filing, its Notes Payables stood at $55000.0 for Q1 2024, which was down 9167.93% from $41000.0 recorded in Q4 2023.
- In the past 5 years, Recursion Pharmaceuticals' Notes Payables registered a high of $3.1 million during Q2 2021, and its lowest value of $41000.0 during Q4 2023.
- Moreover, its 5-year median value for Notes Payables was $96000.0 (2022), whereas its average is $645428.6.
- Per our database at Business Quant, Recursion Pharmaceuticals' Notes Payables tumbled by 9703.35% in 2022 and then surged by 63157.89% in 2023.
- Quarter analysis of 5 years shows Recursion Pharmaceuticals' Notes Payables stood at $1.1 million in 2020, then plummeted by 91.61% to $90000.0 in 2021, then grew by 7.78% to $97000.0 in 2022, then plummeted by 57.73% to $41000.0 in 2023, then skyrocketed by 34.15% to $55000.0 in 2024.
- Its Notes Payables was $55000.0 in Q1 2024, compared to $41000.0 in Q4 2023 and $695000.0 in Q3 2023.